Title:
METHOD AND COMPOSITIONS FOR TREATING THE INFLAMMATORY RESPONSE
Document Type and Number:
WIPO Patent Application WO2000072799
Kind Code:
A3
Abstract:
Agonists of A2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.
More Like This:
Inventors:
LINDEN JOEL M (US)
SULLIVAN GAIL W (US)
SAREMBOCK IAN J (US)
SCHELD W MICHAEL (US)
SULLIVAN GAIL W (US)
SAREMBOCK IAN J (US)
SCHELD W MICHAEL (US)
Application Number:
PCT/US2000/014548
Publication Date:
July 12, 2001
Filing Date:
May 26, 2000
Export Citation:
Assignee:
UNIV VIRGINIA (US)
LINDEN JOEL M (US)
SULLIVAN GAIL W (US)
SAREMBOCK IAN J (US)
SCHELD W MICHAEL (US)
LINDEN JOEL M (US)
SULLIVAN GAIL W (US)
SAREMBOCK IAN J (US)
SCHELD W MICHAEL (US)
International Classes:
A61K31/00; A61K45/06; (IPC1-7): A61K31/00; A61K31/7076; A61P29/00
Domestic Patent References:
| WO1998057651A1 | 1998-12-23 | |||
| WO1999034804A1 | 1999-07-15 |
Foreign References:
| US5877180A | 1999-03-02 |
Other References:
SULLIVAN ET AL.: "Role of A2a adenosine receptors in inflammation", DRUG DEVELOPMENT RESEARCH, vol. 45, no. 3-4, 1998, pages 103 - 112, XP000978332
BUSTER B(A) ET AL: "The effect of adenosine receptor agonists on neutrophil pleocytosis and blood-brain barrier pathophysiology in experimental bacterial meningitis", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,XX,XX, vol. 37, 1997, pages 39, XP002104913
SULLIVAN GW ET AL: "The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY,US,ELMSFORD,NY, vol. 17, no. 10, 1995, pages 793 - 803, XP002104914, ISSN: 0192-0561
SULLIVAN ET AL.: "Neutrophil A2a adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with type IV phosphodiesterase inhibitor , Rolipram", JOURNAL OF INFECTIOUS DISEASES, vol. 180, no. 5, November 1999 (1999-11-01), pages 1550 - 1560, XP000978330
BUSTER B(A) ET AL: "The effect of adenosine receptor agonists on neutrophil pleocytosis and blood-brain barrier pathophysiology in experimental bacterial meningitis", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,XX,XX, vol. 37, 1997, pages 39, XP002104913
SULLIVAN GW ET AL: "The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY,US,ELMSFORD,NY, vol. 17, no. 10, 1995, pages 793 - 803, XP002104914, ISSN: 0192-0561
SULLIVAN ET AL.: "Neutrophil A2a adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with type IV phosphodiesterase inhibitor , Rolipram", JOURNAL OF INFECTIOUS DISEASES, vol. 180, no. 5, November 1999 (1999-11-01), pages 1550 - 1560, XP000978330
Download PDF:
Previous Patent: PORTABLE, SELF-CONTAINED APPARATUS FOR DEEP VEIN THROMBOSIS (DVT) PROPHYLAXIS
Next Patent: IL-8 RECEPTOR ANTAGONISTS
Next Patent: IL-8 RECEPTOR ANTAGONISTS